Table 1.
Demographic and clinical information for all study participants at baseline (PD: n = 30; HC: n = 15) and for the PD subgroup at baseline and 19.9 ± 3.8 months follow-up (PDFU: n = 15). Independent-samples t-test was used to assess the difference between PD and healthy controls at baseline. For the PD follow-up group, Wilcoxon signed-rank and paired-samples t-test were used to assess the difference between baseline and follow-up.
| Baseline: PD (n = 30); HC (n = 15) | ||||
|---|---|---|---|---|
| PD | HC | Statistic | p | |
| Gender (M:F) | 24:6 | 8 : 7 | ||
| Age (years) a | 55.4 ± 7.1 | 53.15 ± 11.4 | t(19.674) = 0.696 | 0.494 |
| Disease duration (years) a | 5.8 ± 2.2 | N/A | ||
| UPDRS-III a | 31.3 ± 10.6 | N/A | ||
| UPDRS-III Bradykinesia-Rigidity a | 22.4 ± 8.1 | N/A | ||
| UPDRS-III Tremor a | 6.2 ± 5.3 | N/A | ||
| Hoehn & Yahr Scale b | 2.0 (0.0) | N/A | ||
| LED a | 670.3 ± 361.8 | N/A | ||
| Follow-Up: PDFU (n = 15) | ||||
| Baseline | Follow-Up | Statistic | p | |
| Gender (M:F) | 12:3 | 12:3 | ||
| Age (years) a | 53.0 ± 7.2 | 54.7 ± 7.1 | t(14) = 26.445 | < 0.001 * |
| Disease duration (years) a | 6.0 ± 2.2 | 7.7 ± 2.0 | t(14) = 26.234 | < 0.001 * |
| UPDRS-III a | 31.4 ± 12.0 | 35.9 ± 10.9 | t(14) = 2.003 | 0.065 |
| UPDRS-III Bradykinesia-Rigidity a | 22.4 ± 9.6 | 25.2 ± 8.9 | t(14) = 1.925 | 0.075 |
| UPDRS-III Tremor a | 6.9 ± 4.5 | 8.3 ± 4.2 | t(14) = 1.514 | 0.152 |
| Hoehn & Yahr Scale b | 2.0 (0.0) | 2.0 (0.0) | Z = 1.7 | 0.083 |
| LED a | 771.7 ± 386.5 | 906.3 ± 235.7 | t(14) = 2.156 | 0.046 * |
a Data are presented as Mean ± SD.
b Data are presented as Median (Interquartile Range).
* Indicates p < 0.05
LED = L-dopa equivalent dose (mg).
UPDRS = Unified Parkinson’s disease rating scale.
The UPDRS and H&Y scale were assessed in the practically defined off-medication state.